Short Sellers Beware: This Marijuana Stock Is Flying High

Cannabis investors shouldn’t count out Aphria Inc. (TSX:APHA)(NYSE:APHA) just yet. The third-largest marijuana producer is destined for bigger growth in the very near future.

Upwards momentum

Image source: Getty Images

The much-maligned Aphria Inc. (TSX:APHA)(NYSE:APHA) is notably beating the odds of late. This $2.3 billion producer and seller of medical cannabis almost got delisted from the TSX two years ago on allegations of non-compliance to listing requirements. Short selling issues also hounded the Leamington-based firm.

However, the dust has settled and Aphria remains on the big board, both in Canada and the U.S. Now that the turbulence is over, the excitement is back. Investors are taking Aphria more seriously this time. The growth potential is there given the positive developments happening in the present.

Spectacular revenue growth

It’s hard to alienate Aphria from the industry peers if you look into the company’s financial metrics. The year-on-year revenue growth of +617% is spectacular by any measure. Still, investors were generally disappointed. Were it not for the contribution of recently acquired CC Pharma, Aphria would be in quicksand.

But how can you quickly dismiss the third-largest grower in Canada moving forward? With a projected peak annual output of 115,000 kilos this year and 255,000 kilos in the years thereafter, Aphria is a force to reckon with in the cannabis space.

APHA is not underperforming, as the stock is doing better than expected. The current price of $9.34% represents a +19.0% jump from the 2018 year-end closing price. Aphria is taking it one step at a time to achieve long-term goals, which will be reflected in the stock performance once the company gets going again.

Aiming for global leadership

Management’s decision temper its beast mode will be good in the long run. And more laws favouring the use of marijuana for medical purposes are forthcoming. Essentially, the company is not late in the green rush. There’s no reason to doubt that Aphria remains a rare value play.

Like the industry giants, Aphria is aiming for global leadership in the cannabis spectrum. The order of the day is to capitalize on its licensed distribution network in Canada. They also own rights to sell in the U.S., Africa, Europe, and South America.

If the company can prove its mettle and deliver results in the near-term, a strong partner will come knocking. Aphria needs to build a strong partnership so it can penetrate the international markets. In the meantime, the company can continue cementing its foothold in medical marijuana and cannabis oil while waiting.

Gigantic upside potential

Aphria has a competitive advantage because it owns two automated and highly sophisticated cultivation facilities: Aphria One and Aphria Diamond. Cannabis investors would like to see Aphria efficiently ramp up production to achieve the desired economies of scale.

The turning point will come this summer. Aphria’s ambitious sales target of US$500 million by year-end and subsequent US$1 billion by year-end 2020 might not be a hallucination after all.

Short-sellers should stay on the sidelines and keep a close watch. The company is back on track: massive revenue growth and hopefully the elusive profits are just around the corner.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Christopher Liew has no position in any of the stocks mentioned.

More on Cannabis Stocks

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Are Cannabis Stocks Still a Thing in 2023?

The whole question of whether cannabis stocks are still relevant in 2023 is an interesting one. Here's my take on…

Read more »

A cannabis plant grows.
Cannabis Stocks

Why Canopy Growth Stock Fell 72% Last Year

Canopy Growth stock is a beaten-up cannabis giant that is trading at a discount compared to historical multiples. But is…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is SNDL Stock a Buy in January 2023?

SNDL is among the worst-performing cannabis stocks in the last three years. But is SNDL stock a buy right now?

Read more »

a person watches a downward arrow crash through the floor
Cannabis Stocks

Why Tilray Stock Fell Almost 60% in 2022

Tilray is a Canadian cannabis stock that is down 93% from all-time highs. Let's see if TLRY stock is a…

Read more »